Generalized Anxiety Disorder Clinical Trial
Official title:
The Potential of Virtual Reality as Anxiety Management Tool: a Randomised Controlled Study in a Sample of Patients Affected by Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD) is a psychiatric disease characterized by long-lasting
anxiety that is not focused on a specific object or situation. According to the DSM-IV-TR
the essential feature of GAD is at least six months of "excessive anxiety and worry" about a
variety of events and situations. Anxiety and worry are often accompanied by a variety of
physical symptoms like restlessness, being easily fatigued, difficulty concentrating,
irritability, muscle tension and disturbed sleep. The high prevalence of GAD in the general
population and the severe limitations it causes point out the necessity to find new
strategies to treat it in a more efficient way. Within the treatment of GAD, physical
(relaxation and controlled breathing), behavioral (visualization and controlled exposure)
and cognitive control strategies (challenging negative thoughts) represent a key part of the
treatment, even if they are hard to be learned. Given the features of this disease and its
pervasive effect on patient's personal, occupational and affective life, we thought it could
benefit from an ubiquitous treatment.We suggested, then, to improve the treatment of GAD
through the use of a biofeedback enhanced virtual reality (VR) system used for relaxation,
controlled exposure and SIT. The use of SIT in the context of GAD is motivated by the
acknowledgment that sometimes stressors can't be avoided or altered and then patients can't
apply strategies focused on finding solutions. In these instances, coping effort should be
directed to emotionally palliative set of responses such as acceptance, reframing and
perspective thinking. All these cognitive changes are facilitated if a concomitant
relaxation is induced. The treatment involves two virtual reality components:
I) an immersive virtual reality system experienced in the therapist's office;
II) a mobile exposure system allowing patients to perform the virtual experience in an
outpatient setting. The role of the mobile exposure system is the following:
- To present and structure emotionally relevant contents in an ubiquitous context.
- To verify the compliance of the patient and eventually alert patient/therapist;
- To track in real-time the emotional level of the patient and record it for later
assessment by the therapist;
- To provide a feedback to the patient able to help him in coping with the contents;
- To automatically contact the therapist if the emotional level is higher than a preset
cut-off value defined by the therapist.
The patients were randomly assigned to the following groups: (1) the VR and Mobile group
(VRMB) including biofeedback - 7 subjects; (2) the VR and Mobile group (VRM) without
biofeedback - 9 subjects; (3) the waiting list (WL) group - 8 subjects:
1. Virtual Reality + Mobile Phone without Biofeedback Condition (VRM). In this
experimental condition patients received an eight-session VR-based treatment including
relaxation and exposure. In sessions 1 to 6, the patient explored a beautiful VR
tropical island (experienced with a head-mounted display and head-tracking) following a
predefined path leading to different relaxing areas: Campfire, Beach and Waterfall. In
these areas the patients started to relax by observing the flickering campfire,
watching waves lapping gently on a shore, or looking to the waterfall and fish pond.
Each experience was supported by an audio narrative based on progressive muscle
relaxation and/or autogenic techniques. All the environments were developed by the
ESIEA INTREPID team (J.L. Dautin, J. Ardouin, F. Crison and M. Le Renard -www.esiea.fr)
using the 3DVIA 4.1 Virtools toolkit by Dassault Systèmes - www.virtools.com.To improve
the efficacy of the training and to increase the effects of relaxation, patients
experienced at home, using a mobile phone, on a non-navigable version of the same
virtual reality environment experienced during the therapy. The patient was asked to
train relaxation abilities at least once a day for the entire duration of the treatment
following the treatment plan provided by the therapist. In session 7 and 8 the patients
explored again the island reaching a Gazebo in which they are exposed to pre-selected
words or images related to their personal stressful events. The patients were then
asked to use the learned relaxation techniques to cope with them.
2. Virtual Reality + Mobile Phone with Biofeedback Condition (VRMB). The patients
experienced the same protocol described above, but with the biofeedback support (see
Figure 2). Specifically, in the sessions with the therapist, HR variations were used to
modify specific features of the virtual environment:
1. Campfire (sessions 1-2). HR controls the fire intensity: a reduction of the
patient's physiological activation reduces fire intensity until it disappears;
2. Beach (sessions 3-4). HR controls the movement of the waves: a reduction of the
patient's physiological activation reduces the movement of the waves until the
ocean becomes completely calm;
3. Waterfall (sessions 5-6): HR controls the movement of the water: a reduction of
the patient's physiological activation reduces the movement of the water until the
water flow becomes completely still;
4. Gazebo (sessions 7-8): HR controls the size of a stressful image or video: a
reduction of the patient's physiological activation reduces the size of the
stimulus until it disappears. This exercise is designed following the procedure of
SIT.
3. Waiting List Condition (WL). This was a control condition, in which patients were
included in a waiting list and not received any kind of relaxation training.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |